Trials / Completed
CompletedNCT00057642
Improving Retention of Hispanics Receiving Antidepressant Therapy
Improving Hispanic Retention in Antidepressant Therapy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- New York State Psychiatric Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will develop an intervention that will increase the retention of Hispanics with major depression in antidepressant therapy.
Detailed description
Despite major advances in the treatment of psychiatric disorders, Hispanics continue to underutilize mental health services relative to their own mental health needs. Cultural factors are important causes of underutilization. To date, however, attempts to boost utilization by improving the cultural congruence of psychiatric services have not focused on retaining Hispanics in antidepressant therapy. Motivational Interviewing (MI) is a time-limited psychotherapy that has successfully improved treatment retention among patients with dually diagnosed substance abuse and psychiatric disorders. During Phase I of this study, MI is adapted for use as an adjunctive therapy with antidepressant treatment and culturally adapted to Hispanic participants. In Phase II, participants receive sertraline for 12 weeks and participate in four sessions of MI therapy as a supplementary intervention designed to encourage treatment retention. Participants who are intolerant to sertraline or have an inadequate response by Week 6 are switched to venlafaxine ER while continuing to receive MI and to complete study assessments. A follow-up interview is conducted 6 months after the termination of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sertraline | |
| DRUG | Venlafaxine Extended Release |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2003-04-07
- Last updated
- 2013-08-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00057642. Inclusion in this directory is not an endorsement.